Obesity and reproductive function of women: epigenetic and somato-psychological features
Abstract
The review article presents data on the effects of obesity on the female reproductive system and offspring of mothers with overweight or obesity, such as infertility, miscarriages, premature birth, stillbirth, congenital anomalies and prematurity, as well as a high risk of cesarean section. Obesity accompanies polycystic ovary syndrome, worsening the metabolic profile and increasing the risk of developing depression and eating disorders. Maternal obesity and hyperglycemia are able to influence the formation of the fetus by epigenetic mechanisms without affecting the nucleotide sequences. Subsequently, the metabolic and cardiovascular risks increase in the descendants of obese or overweight mothers and gestational diabetes. Patients with obesity are characterized by a folic acid deficiency and a deficiency of the luteal phase. Exogenous administration of these substances improves pregnancy outcomes and prevents congenital malformations.
About the Authors
Elena N. AndreevaEndocrinology Research Centre; A.I. Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
MD, PhD, Professor
Yulia S. Absatarova
Endocrinology Research Centre
Russian Federation
Ekaterina V. Sheremetyeva
Endocrinology Research Centre
Russian Federation
MD, PhD
Valentina A. Fursenko
Endocrinology Research Centre
Russian Federation
MD, postgraduate student
References
1. Who.int [Internet]. Всемирная Организация Здравоохранения. Центр СМИ. Информационный бюллетень «Ожирение и избыточный вес». [updated 2018 Feb 16; cited 2019 Jan 28]. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
2. Who.int [Internet]. World Health Organisation Global Health Observatory data repository. Prevalence of obesity among adults, BMI ≥ 30, age-standardized. Estimates by country. [updated 2017 Sep 22; cited 2019 Jan 28]. Available from: http://apps.who.int/gho/data/node.main.A900A?lang=en
3. Rachoń D, Teede H. Ovarian function and obesity—Interrelationship, impact on women’s reproductive lifespan and treatment options. Mol Cell Endocrinol. 2010;316(2):172-179. doi: 10.1016/j.mce.2009.09.026
4. Moran LJ, Norman RJ, Teede HJ. Metabolic risk in PCOS: phenotype and adiposity impact. Trends Endocrinol Metab. 2015;26(3):136-143. doi: 10.1016/j.tem.2014.12.003
5. Setji TL, Brown AJ. Polycystic Ovary syndrome: Update on diagnosis and treatment. Am J Med. 2014. doi: 10.1016/j.amjmed.2014.04.017
6. Dokras A. Mood and anxiety disorders in women with PCOS. Steroids. 2012;77(4):338-341. doi: 10.1016/j.steroids.2011.12.008
7. Karacan E, Caglar GS, Gürsoy AY, Yilmaz MB. Body Satisfaction and Eating Attitudes among Girls and Young Women with and without Polycystic Ovary Syndrome. J Pediatr Adolesc Gynecol. 2014;27(2):72-77. doi: 10.1016/j.jpag.2013.08.003
8. Lee I, Cooney LG, Saini S, et al. Increased risk of disordered eating in polycystic ovary syndrome. Fertil Steril. 2017;107(3):796-802. doi: 10.1016/j.fertnstert.2016.12.014
9. Larsson I, Hulthén L, Landén M, et al. Dietary intake, resting energy expenditure, and eating behavior in women with and without polycystic ovary syndrome. Clin Nutr. 2016;35(1):213-218. doi: 10.1016/j.clnu.2015.02.006
10. Butterworth J, Deguara J, Borg C-M. Bariatric Surgery, Polycystic Ovary Syndrome, and Infertility. J Obes. 2016;2016:1-6. doi: 10.1155/2016/1871594
11. Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602-1618. doi: 10.1093/humrep/dey256
12. Foroozanfard F, Rafiei H, Samimi M, et al. The effects of dietary approaches to stop hypertension diet on weight loss, anti-Müllerian hormone and metabolic profiles in women with polycystic ovary syndrome: A randomized clinical trial. Clin Endocrinol (Oxf). 2017;87(1):51-58. doi: 10.1111/cen.13333
13. Guenard F, Deshaies Y, Cianflone K, et al. Differential methylation in glucoregulatory genes of offspring born before vs. after maternal gastrointestinal bypass surgery. Proc Natl Acad Sci. 2013;110(28):11439-11444. doi: 10.1073/pnas.1216959110
14. Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012;18(6):618-637. doi: 10.1093/humupd/dms030
15. van der Steeg JW, Steures P, Eijkemans MJC, et al. Obesity affects spontaneous pregnancy chances in subfertile, ovulatory women. Hum Reprod. 2007;23(2):324-328. doi: 10.1093/humrep/dem371
16. Moran LJ, Noakes M, Clifton PM, et al. Dietary Composition in Restoring Reproductive and Metabolic Physiology in Overweight Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2003;88(2):812-819. doi: 10.1210/jc.2002-020815
17. Gesink Law DC, Maclehose RF, Longnecker MP. Obesity and time to pregnancy. Hum Reprod. 2006;22(2):414-420. doi: 10.1093/humrep/del400
18. Shah DK, Missmer SA, Berry KF, et al. Effect of Obesity on Oocyte and Embryo Quality in Women Undergoing In Vitro Fertilization. Obstet Gynecol. 2011;118(1):63-70. doi: 10.1097/AOG.0b013e31821fd360
19. Luke B, Brown MB, Stern JE, et al. Female obesity adversely affects assisted reproductive technology (ART) pregnancy and live birth rates. Hum Reprod. 2011;26(1):245-252. doi: 10.1093/humrep/deq306
20. Institute of Medicine and National Research Council. Weight Gain During Pregnancy: Reexamining the Guidelines. Washington, DC: The National Academies Press; 2009. doi: 10.17226/12584
21. Restall A, Taylor RS, Thompson JMD, et al. Risk Factors for Excessive Gestational Weight Gain in a Healthy, Nulliparous Cohort. J Obes. 2014;2014:1-9. doi: 10.1155/2014/148391
22. Deputy NP, Sharma AJ, Kim SY, Hinkle SN. Prevalence and Characteristics Associated With Gestational Weight Gain Adequacy. Obstet Gynecol. 2015;125(4):773-781. doi: 10.1097/AOG.0000000000000739
23. Margerison Zilko CE, Rehkopf D, Abrams B. Association of maternal gestational weight gain with short- and long-term maternal and child health outcomes. Am J Obstet Gynecol. 2010;202(6):574.e1-574.e8. doi: 10.1016/j.ajog.2009.12.007
24. Silveira ML, Ertel KA, Dole N, Chasan-Taber L. The role of body image in prenatal and postpartum depression: a critical review of the literature. Arch Womens Ment Health. 2015;18(3):409-421. doi: 10.1007/s00737-015-0525-0
25. Skouteris H, Carr R, Wertheim EH, et al. A prospective study of factors that lead to body dissatisfaction during pregnancy. Body Image. 2005;2(4):347-361. doi: 10.1016/j.bodyim.2005.09.002
26. Boudet-Berquier J, Salanave B, Desenclos J-C, Castetbon K. Sociodemographic factors and pregnancy outcomes associated with prepregnancy obesity: effect modification of parity in the nationwide Epifane birth-cohort. BMC Pregnancy Childbirth. 2017;17(1):273. doi: 10.1186/s12884-017-1456-8
27. Waddington CH. The Epigenotype. Int J Epidemiol. 2012;41(1):10-13. doi: 10.1093/ije/dyr184
28. Carolan-Olah M, Duarte-Gardea M, Lechuga J. A critical review: early life nutrition and prenatal programming for adult disease. J Clin Nurs. 2015;24(23-24):3716-3729. doi: 10.1111/jocn.12951
29. Yan X, Huang Y, Zhao J-X, et al. Maternal obesity downregulates microRNA let-7g expression, a possible mechanism for enhanced adipogenesis during ovine fetal skeletal muscle development. Int J Obes. 2013;37(4):568-575. doi: 10.1038/ijo.2012.69
30. Frias A, Grove K. Obesity: A Transgenerational Problem Linked to Nutrition during Pregnancy. Semin Reprod Med. 2012;30(06):472-478. doi: 10.1055/s-0032-1328875
31. Dabelea D, Crume T. Maternal Environment and the Transgenerational Cycle of Obesity and Diabetes. Diabetes. 2011;60(7):1849-1855. doi: 10.2337/db11-0400
32. Dante G, Vaccaro V, Facchinetti F. Use of progestagens during early pregnancy. Facts Views Vis Obgyn. 2013;5(1):66–71. PMID: 24753930.
33. Hou M, Chu Z, Liu T, et al. A high-fat maternal diet decreases adiponectin receptor-1 expression in offspring. J Matern Neonatal Med. 2015;28(2):216-221. doi: 10.3109/14767058.2014.914489
34. Fan L, Lindsley SR, Comstock SM, et al. Maternal high-fat diet impacts endothelial function in nonhuman primate offspring. Int J Obes. 2013;37(2):254-262. doi: 10.1038/ijo.2012.42
35. Ornoy A. Prenatal origin of obesity and their complications: Gestational diabetes, maternal overweight and the paradoxical effects of fetal growth restriction and macrosomia. Reprod Toxicol. 2011;32(2):205-212. doi: 10.1016/j.reprotox.2011.05.002
36. Chen C-P. Prenatal findings and the genetic diagnosis of fetal overgrowth disorders: Simpson-Golabi-Behmel syndrome, Sotos syndrome, and Beckwith-Wiedemann syndrome. Taiwan J Obstet Gynecol. 2012;51(2):186-191. doi: 10.1016/j.tjog.2012.04.004
37. Marchi J, Berg M, Dencker A, Olander EK, Begley C. Risks associated with obesity in pregnancy, for the mother and baby: a systematic review of reviews. Obes Rev. 2015;16(8):621-638. doi: 10.1111/obr.12288
38. Xu J, Ye J, Wu Y, et al. Reduced Fetal Telomere Length in Gestational Diabetes. Frasch MG, ed. PLoS One. 2014;9(1):e86161. doi: 10.1371/journal.pone.0086161
39. Ryckman K, Smith C. Epigenetic and developmental influences on the risk of obesity, diabetes, and metabolic syndrome. Diabetes, Metab Syndr Obes Targets Ther. 2015;2015(8):295-302. doi: 10.2147/DMSO.S61296
40. Monk M, Boubelik M, Lehnert S. Temporal and regional changes in DNA methylation in the embryonic, extraembryonic and germ cell lineages during mouse embryo development. Development. 1987;99(3):371-382. PMID: 3653008
41. Cardozo E, Pavone ME, Hirshfeld-Cytron JE. Metabolic syndrome and oocyte quality. Trends Endocrinol Metab. 2011;22(3):103-109. doi: 10.1016/j.tem.2010.12.002
42. Zambrano E, Martínez-Samayoa PM, Bautista CJ, et al. Sex differences in transgenerational alterations of growth and metabolism in progeny (F2) of female offspring (F1) of rats fed a low protein diet during pregnancy and lactation. J Physiol. 2005;566(1):225-236. doi: 10.1113/jphysiol.2005.086462
43. Timmermans S, Steegers-Theunissen RP, Vujkovic M, et al. The Mediterranean diet and fetal size parameters: the Generation R Study. Br J Nutr. 2012;108(08):1399-1409. doi: 10.1017/S000711451100691X
44. Lillycrop KA, Phillips ES, Jackson AA, Hanson MA, Burdge GC. Dietary Protein Restriction of Pregnant Rats Induces and Folic Acid Supplementation Prevents Epigenetic Modification of Hepatic Gene Expression in the Offspring. J Nutr. 2005;135(6):1382-1386. doi: 10.1093/jn/135.6.1382
45. Cawley S, Mullaney L, McKeating A, Farren M, McCartney D, Turner MJ. A review of European guidelines on periconceptional folic acid supplementation. Eur J Clin Nutr. 2016;70(2):143-154. doi: 10.1038/ejcn.2015.131
46. Bailey LB, Stover PJ, McNulty H, et al. Biomarkers of Nutrition for Development—Folate Review. J Nutr. 2015;145(7):1636S-1680S. doi: 10.3945/jn.114.206599
47. Mojtabai R. Body mass index and serum folate in childbearing age women. Eur J Epidemiol. 2004;19(11):1029-1036. doi: 10.1007/s10654-004-2253-z
48. Knight BA, Shields BM, Brook A, et al. Lower Circulating B12 Is Associated with Higher Obesity and Insulin Resistance during Pregnancy in a Non-Diabetic White British Population. Sengupta S, editor. PLoS One. 2015;10(8):e0135268. doi: 10.1371/journal.pone.0135268
49. Shen M, Chaudhry SH, MacFarlane AJ, et al. Serum and red-blood-cell folate demonstrate differential associations with BMI in pregnant women. Public Health Nutr. 2016;19(14):2572-2579. doi: 10.1017/S1368980016000756
50. Dean SV., Lassi ZS, Imam AM, Bhutta ZA. Preconception care: nutritional risks and interventions. Reprod Health. 2014;11(Suppl 3):S3. doi: 10.1186/1742-4755-11-S3-S3
51. Blode H, Diefenbach, Trummer, et al. EE-drospirenone-levomefolate calcium versus EE-drospirenone + folic acid: folate status during 24 weeks of treatment and over 20 weeks following treatment cessation. Int J Womens Health. 2013;2013(5):149-163. doi: 10.2147/IJWH.S37254
52. Castaño PM, Aydemir A, Sampson-Landers C, Lynen R. The folate status of reproductive-aged women in a randomised trial of a folate-fortified oral contraceptive: dietary and blood assessments. Public Health Nutr. 2014;17(06):1375-1383. doi: 10.1017/S1368980013000864
53. Pfeifer S, Fritz M, Goldberg J, et al. The clinical relevance of luteal phase deficiency: a committee opinion. Fertil Steril. 2012;98(5):1112-1117. doi: 10.1016/j.fertnstert.2012.06.050
54. Jain A, Polotsky AJ, Rochester D, et al. Pulsatile Luteinizing Hormone Amplitude and Progesterone Metabolite Excretion Are Reduced in Obese Women. J Clin Endocrinol Metab. 2007;92(7):2468-2473. doi: 10.1210/jc.2006-2274
55. Vannuccini S, Clifton VL, Fraser IS, et al. Infertility and reproductive disorders: impact of hormonal and inflammatory mechanisms on pregnancy outcome. Hum Reprod Update. 2016;22(1):104-115. doi: 10.1093/humupd/dmv044
56. Schindler AE. Progestogen deficiency and endometrial cancer risk. Maturitas. 2009;62(4):334-337. doi: 10.1016/j.maturitas.2008.12.018
57. Nawaz FH, Khalid R, Naru T, Rizvi J. Does continuous use of metformin throughout pregnancy improve pregnancy outcomes in women with polycystic ovarian syndrome? J Obstet Gynaecol Res. 2008;34(5):832-837. doi: 10.1111/j.1447-0756.2008.00856.x
58. Costello MF, Eden JA. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril. 2003;79(1):1-13. doi: 10.1016/S0015-0282(02)04554-5
59. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, et al. Effects of Metformin on Early Pregnancy Loss in the Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2002;87(2):524-529. doi: 10.1210/jcem.87.2.8207
60. Ben-Haroush A, Yogev Y, Hod M. Epidemiology of gestational diabetes mellitus and its association with Type 2 diabetes. Diabet Med. 2004;21(2):103-113. doi: 10.1046/j.1464-5491.2003.00985.x
61. Rai R, Backos M, Rushworth F, Regan L. Polycystic ovaries and recurrent miscarriage—a reappraisal. Hum Reprod. 2000;15(3):612-615. doi: 10.1093/humrep/15.3.612
62. Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod. 2002;17(11):2858-2864. doi: 10.1093/humrep/17.11.2858
63. Макацария А.Д., Передеряева Е.Б., Пшеничникова Т.Б. Особенности применения натурального прогестерона в профилактике осложнений беременности у женщин с метаболическим синдромом // Эффективная фармакотерапия. – 2008. – №5. – С.11-14. [Makatsariya AD, Perederyaeva EB, Pshenichnikova TB. Osobennosti primeneniya natural'nogo progesterona v profilaktike oslozhnenii beremennosti u zhenshchin s metabolicheskim sindromom. Èffektivnaâ farmakoterapiâ. 2008;(5):11-14. (in Russ.)]
64. Arredondo F, Noble LS. Endocrinology of Recurrent Pregnancy Loss. Semin Reprod Med. 2006;24(01):033-039. doi: 10.1055/s-2006-931799
65. Norwitz ER, Bonney EA, Snegovskikh V V., et al. Molecular Regulation of Parturition: The Role of the Decidual Clock. Cold Spring Harb Perspect Med. 2015;5(11):a023143. doi: 10.1101/cshperspect.a023143
66. Dumesic DA, Lobo RA. Cancer risk and PCOS. Steroids. 2013;78(8):782-785. doi: 10.1016/j.steroids.2013.04.004
67. Daya S, Gunby J. Luteal phase support in assisted reproduction cycles. In: Daya S, editor. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2004. doi: 10.1002/14651858.CD004830
68. Salehpour S, Tamimi M, Saharkhiz N. Comparison of oral dydrogesterone with suppository vaginal progesterone for luteal-phase support in in vitro fertilization (IVF): A randomized clinical trial. Iran J Reprod Med. 2013;11(11):913-918. PMID: 24639716
69. Tomic V, Tomic J, Klaic DZ, Kasum M, Kuna K. Oral dydrogesterone versus vaginal progesterone gel in the luteal phase support: randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2015;186:49-53. doi: 10.1016/j.ejogrb.2014.11.002
70. Адамян Л.В., Артымук Н.В., Белокриницкая Т.В., и др. Выкидыш в ранние сроки беременности: диагностика и тактика ведения. Клинические рекомендации (протокол лечения). — М.: Российское общество акушеров-гинекологов, 2016. [Adamyan LV, Artymuk NV, Belokrinitskaya TV, et al. Vykidysh v rannie sroki beremennosti: diagnostika i taktika vedeniya. Klinicheskie rekomendatsii (protokol lecheniya). Moscow: Rossiiskoe obshchestvo akusherov-ginekologov; 2016. (In Russ.)]
71. Dennerstein L, Spencer-Gardner C, Gotts G, et al. Progesterone and the premenstrual syndrome: a double blind crossover trial. BMJ. 1985;290(6482):1617-1621. doi: 10.1136/bmj.290.6482.1617
72. Sitruk-Ware R. Non-clinical studies of progesterone. Climacteric. 2018;21(4):315-320. doi: 10.1080/13697137.2018.1463982
73. Keum N, Greenwood DC, Lee DH, et al. Adult Weight Gain and Adiposity-Related Cancers: A Dose-Response Meta-Analysis of Prospective Observational Studies. JNCI J Natl Cancer Inst. 2015;107(2):djv088. doi: 10.1093/jnci/djv088
74. Haggerty AF, Huepenbecker S, Sarwer DB, et al. The use of novel technology-based weight loss interventions for obese women with endometrial hyperplasia and cancer. Gynecol Oncol. 2016;140(2):239-244. doi: 10.1016/j.ygyno.2015.11.033
75. Anveden Å, Taube M, Peltonen M, et al. Long-term incidence of female-specific cancer after bariatric surgery or usual care in the Swedish Obese Subjects Study. Gynecol Oncol. 2017;145(2):224-229. doi: 10.1016/j.ygyno.2017.02.036
76. Benedetto C, Salvagno F, Canuto EM, Gennarelli G. Obesity and female malignancies. Best Pract Res Clin Obstet Gynaecol. 2015;29(4):528-540. doi: 10.1016/j.bpobgyn.2015.01.003
77. Yang S, Thiel KW, Leslie KK. Progesterone: the ultimate endometrial tumor suppressor. Trends Endocrinol Metab. 2011;22(4):145-152. doi: 10.1016/j.tem.2011.01.005
78. Gottschau M, Kjaer SK, Jensen A, Munk C, Mellemkjaer L. Risk of cancer among women with polycystic ovary syndrome: A Danish cohort study. Gynecol Oncol. 2015;136(1):99-103. doi: 10.1016/j.ygyno.2014.11.012
Supplementary files
Review
For citations:
Andreeva E.N., Absatarova Yu.S., Sheremetyeva E.V., Fursenko V.A. Obesity and reproductive function of women: epigenetic and somato-psychological features. Obesity and metabolism. 2019;16(2):9-15. (In Russ.)
Views:
8782
Email this article 
